Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral Versus Central.

Trial Profile

Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral Versus Central.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Etoricoxib (Primary)
  • Indications Postoperative pain
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2012 Actual patient number changed from 12 to 23 as reported by ClinicalTrials.gov.
    • 12 Jul 2011 Additional lead trial centre identified as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top